AbbVie Gets CHMP Backing for Rinvoq in Vitiligo, Alopecia Areata
By Colin Kellaher
AbbVie said a key European regulatory committee has recommended expanded approval of its blockbuster autoimmune drug Rinvoq in the autoimmune diseases vitiligo and alopecia areata.
AbbVie on Monday said the positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use cover Rinvoq for the treatment of adults and adolescents with severe alopecia areata, which causes a range of hair loss patterns, and with the depigmenting disorder non-segmental vitiligo.
The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in the coming months, the North Chicago, Ill., biopharmaceutical company said.
AbbVie said a green light would make Rinvoq the first systemic medication available in Europe for patients with non-segmental vitiligo, the most common form of vitiligo, which is marked by symmetrical and bilateral depigmented white patches of skin.
AbbVie has previously said it expects revenue from Rinvoq, which is already approved for use in several autoimmune diseases, to top $10 billion this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 29, 2026 06:25 ET (10:25 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States